advertisement
11.16 Vehicles, delivery systems, pharmacokinetics, formulation (26)
Showing records 1 to 25
Search within classification 11.16 Vehicles, delivery systems, pharmacokinetics, formulation45803 Long-term topical antiglaucoma medications cause enhanced Tenon's capsule fibroblast proliferation and abnormal TGF-(beta) and MMP expressions: Potential effects on glaucoma filtering surgery
Leng F; Liu P; Li H; Zhang J
Current Eye Research 2011; 36: 301-309
45804 Ocular surface disease in patients with ocular hypertension and glaucoma
Stewart WC; Stewart JA; Nelson LA
Current Eye Research 2011; 36: 391-398
45442 The influence of ocular surface diseases in the management of glaucoma
Van Went C; Brasnu E; Hamard P; Baudouin C; Labbé A
Journal Français d'Ophtalmologie 2011; 34: 230-237
45610 Effects of glaucoma medications and preservatives on cultured human trabecular meshwork and non-pigmented ciliary epithelial cell lines
Ammar DA; Kahook MK
British Journal of Ophthalmology 2011;
45879 Current dilemmas and controversies in allergic contact dermatitis to ophthalmic medications
Novitskaya ES; Dean SJ; Craig JP; Alexandroff AB
Clinics in Dermatology 2011; 29: 295-299
45881 Effects of benzalkonium chloride- and polyquad-preserved combination glaucoma medications on cultured human ocular surface cells
Ammar DA; Noecker RJ; Kahook MY
Advances in Therapy 2011; 28: 501-510
45734 The use of mucoadhesive polymers to enhance the hypotensive effect of a melatonin analogue, 5-MCA-NAT, in rabbit eyes
Andres-Guerrero V; Molina-Martinez IT; Pera A; de las Heras B; Pintor J; Herrero-Vanrell R
Investigative Ophthalmology and Visual Science 2011; 52: 1507-1515
45454 Comparison of the In Vitro Tolerance and In Vivo Efficacy of Traditional Timolol Maleate Eye Drops versus New Formulations with Bioadhesive Polymers
Andrés-Guerrero V; Vicario-de-la-Torre M; Molina-Martínez IT; Benítez-Del-Castillo JM; García-Feijoo J; Herrero-Vanrell R
Investigative Ophthalmology and Visual Science 2011; 52: 3548-3556
46315 Bioactivation antioxidant and transglycating properties of N-acetylcarnosine autoinduction prodrug of a dipeptide L-carnosine in mucoadhesive drug delivery eye-drop formulation: Powerful eye health application technique and therapeutic platform
Babizhayev MA
Drug Testing and Analysis 2011;
45545 Mucoadhesive microparticles in a rapidly dissolving tablet for sustained drug delivery to the eye
Choy YB; Patel SR; Park JH; McCarey BE; Edelhauser HF; Prausnitz MR
Investigative Ophthalmology and Visual Science 2011; 52: 2627-2633
45911 Force requirements in topical medicine usethe squeezability factor
Connor AJ; Severn PS
Eye 2011; 25: 466-469
46259 Corneal cell culture models: A tool to study corneal drug absorption
Dey S
Expert Opinion on Drug Metabolism and Toxicology 2011; 7: 529-532
45937 Enhancement of anti-glaucoma potential by novel ocular drug delivery system
Gupta S; Gilhotra RM
International Journal of Pharmacy and Pharmaceutical Sciences 2011; 3: 55-58
46186 Enhanced Solubility, Stability, and Transcorneal Permeability of Delta-8-Tetrahydrocannabinol in the Presence of Cyclodextrins
Hippalgaonkar K; Gul W; Elsohly MA; Repka MA; Majumdar S
AAPS PharmSciTech 2011;
45645 Efficacy and safety of topical travoprost with sofzia(registered trademark) preservative for Japanese glaucoma patients
Kanamoto T; Kiuchi Y; Suehiro T; Nakano T; Nakano Y; Hirota A; Miyata A
Hiroshima Journal of Medical Sciences 2010; 59: 71-75
45938 Effect of a single drop of Latanoprost ophthalmic gel on intra ocular pressure in the treatment of glaucoma
Kulkarni SV; Sandeep HN; Shankar MS; Ranjit Kumar P; Someshwara Rao B; Ramesh B; Ashok Kumar PA
International Journal of Pharmaceutical Sciences 2010; 2: 429-435
45917 Novel drug delivery systems for glaucoma
Lavik E; Kuehn MH; Kwon YH
Eye 2011; 25: 578-586
45504 Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system
Liang H; Pauly A; Riancho L; Baudouin C; Brignole-Baudouin F
British Journal of Ophthalmology 2011; 95: 869-875
46095 Effects of osmoprotection on symptoms, ocular surface damage, and tear film modifications caused by glaucoma therapy
Monaco G; Cacioppo V; Consonni D; Troiano P
European Journal of Ophthalmology 2011; 21: 243-250
46266 A poly((epsilon)-caprolactone) device for sustained release of an anti-glaucoma drug
Natu MV; Gaspar MN; Ribeiro CAF; Correia IJ; Silva D; De Sousa HC; Gil MH
Biomedical Materials 2011; 6: 025003
45940 Formulation and evaluation of Latanoprost ophthalmic gels
Sandeep HN; Kulkarni SV; Vinod R; Shankar MS; Someshwara Rao B; Ashok Kumar P
Journal of Global Pharma Technology 2010; 2: 35-39
46101 Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue
Servat JJ; Bernardino CR
Drugs and Aging 2011; 28: 267-282
46292 A timely review of state-of-the-art chronopharmaceuticals synchronized with biological rhythms
Sewlall S; Pillay V; Danckwerts MP; Choonara YE; Ndesendo VM; Du Toit LC
Current Drug Delivery 2010; 7: 370-388
46288 An updated patent review on ocular drug delivery systems with potential for commercial viability
Srivastava R; Pathak K
Recent Patents on Drug Delivery and Formulation 2011; 5: 146-162
46122 Short-term effect of topical antiglaucoma medication on tear-film stability, tear secretion, and corneal sensitivity in healthy subjects
Terai N; Muller-Holz M; Spoerl E; Pillunat LE
Clinical Ophthalmology 2011; 5: 517-525
